Cancer Research  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 43, 1107-1116, March 1, 1983]
© 1983 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barrack, E. R.
Right arrow Articles by Walsh, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrack, E. R.
Right arrow Articles by Walsh, P. C.

Subcellular Distribution of Androgen Receptors in Human Normal, Benign Hyperplastic, and Malignant Prostatic Tissues: Characterization of Nuclear Salt-resistant Receptors1

Evelyn R. Barrack2, Piroska Bujnovszky and Patrick C. Walsh

The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital [E. R. B., P. B., P. C. W.], and The Department of Urology, The Johns Hopkins University School of Medicine [E. R. B., P. B., P. C. W.], Baltimore, Maryland 21205

Two populations of nuclear androgen receptors have been characterized in human prostatic tissue, and the levels and proportions of each were found to differ in normal prostates, benign hyperplastic prostates (BPH), and malignant prostates. A significant percentage (35 to 50%) of total nuclear androgen receptors was associated with the salt-resistant nuclear matrix fraction. The remainder were easily extracted from nuclei by 0.6 M KCI. Optimal conditions for measuring receptors in both compartments involved the use of an inhibitor of proteolysis (phenylmethylsulfonyl fluoride) and the omission of dithiothreitol from buffers. In the presence of dithiothreitol, most of the nuclear salt-resistant receptors were rendered salt extractable. Cytosol androgen receptor levels were not significantly different in normal, BPH, or malignant prostatic tissues. In contrast, the levels and distribution of nuclear salt-extractable and salt-resistant androgen receptors exhibited characteristic patterns. Compared to normal prostatic tissue, nuclear salt-extractable receptors were significantly elevated in both BPH and cancer, whereas nuclear salt-resistant receptors were elevated in BPH but not in cancer. The ratio of salt-extractable to salt-resistant receptors was approximately 1:1 in both normal and BPH tissues and 2:1 in cancer. In addition, a microassay has been developed for the measurement of androgen receptors in the three subcellular compartments of needle biopsy specimens of prostatic cancer. Studies are in progress to determine whether the measurement of both nuclear salt-extractable and salt-resistant receptors may improve the usefulness of receptor levels to predict the hormonal responsiveness of prostatic cancer.

1 Supported by Grant CA-16924 from the National Cancer Institute and Grants AM 19300 and AM 22000 from the National Institute of Arthritis, Metabolism and Digestive Diseases, NIH.

2 To whom requests for reprints should be addressed, at The Brady Urological Institute, Marburg 115, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, Md. 21205.

Received 7/30/82. Accepted 11/23/82.




This article has been cited by other articles:


Home page
EndocrinologyHome page
P. P. Banerjee, S. Banerjee, and T. R. Brown
Increased Androgen Receptor Expression Correlates with Development of Age-Dependent, Lobe-Specific Spontaneous Hyperplasia of the Brown Norway Rat Prostate
Endocrinology, September 1, 2001; 142(9): 4066 - 4075.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1983 by the American Association for Cancer Research.